Montreal, Quebec — January 21, 2026 — Leads & Copy — Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) has announced a shift in its corporate focus, positioning itself as a precision intracellular drug-delivery company. This evolution highlights the company’s commitment to advancing its Accum® platform through internal development and strategic partnerships.
The Accum® platform is designed to enhance intracellular delivery, boosting therapeutic potency while reducing toxicity. This approach aims to unlock the full potential of complex cancer biologics.
According to Defence Therapeutics, Accum® addresses a key challenge in oncology: effective intracellular drug delivery. By improving cellular uptake and payload release, Accum® can increase therapeutic potency at lower doses, potentially reducing toxicity and improving patient access to advanced cancer treatments.
Defence Therapeutics is prioritizing its platform and partnering model through a dual strategy. This includes internal R&D programs and strategic partnerships within the biotech and pharmaceutical sectors. This approach aims to enhance both existing and next-generation assets, such as antibody-drug conjugates (ADCs) and radiopharmaceuticals. The goal is to transform therapies traditionally used in later lines of treatment into safer, more effective first-line options.
Sébastien Plouffe, CEO of Defence Therapeutics, stated that the company’s focus is to solve drug delivery at the cellular level. This will allow cancer therapies, whether developed by Defence or its partners, to reach their full potential. Plouffe added that Accum® is designed to create value for partners and deliver better outcomes for patients.
With this refined positioning, Defence Therapeutics aims to reinforce its commitment to precision oncology, collaboration, and the translation of science into life-changing treatments. The company’s business model is designed to generate value for partners and long-term value for shareholders.
Defence Therapeutics is a publicly traded biotechnology company focused on making cancer treatment more effective and safer. The company’s Accum® precision drug delivery platform enhances the potency of ADCs and other complex biologics at lower doses. This approach aims to reduce side effects and improve access to advanced therapies.
By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence Therapeutics strives to bring transformative therapies to patients.
For further information, contact Sebastien Plouffe, CEO, Founder and Director, at (514) 947-2272 or Splouffe@defencetherapeutics.com.
Source: Defence Therapeutics
